Physician profile
Nathan Radcliffe
NPI 1124229810
$2,121,110.75
in general payments reported to CMS, 2019-2025
45 companies · $365K in 2025
The $365K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $278K · 2020: $270K · 2021: $306K · 2022: $321K · 2023: $326K · 2024: $255K · 2025: $365K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $438K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $289K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $123K · Travel and Lodging: $45K · Food and Beverage: $26K · Honoraria: $24K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $438,164.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $289,020.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $122,950.00 |
| Travel and Lodging | $45,163.58 |
| Food and Beverage | $25,811.33 |
| Honoraria | $24,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $446,956.27 | 2019-2022 | |
| Alcon Vision LLC | $355,687.64 | 2019-2025 | Hydrus Microstent, Rocklatan, Voyager Dslt |
| Abbvie INC. | $207,407.04 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $174,171.87 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $170,425.41 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $113,327.09 | 2019-2021 | |
| Beaver-Visitec International, INC. | $108,358.12 | 2019-2025 | |
| Reichert, INC. | $106,102.50 | 2019-2024 | Tono-Vera Tonometer US Starter Kit Human Rechargable |
| Glaukos Corporation | $67,558.61 | 2019-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Travoprost Intraocular Implant - Idose, Istent Trabecular Micro-Bypass Stent System |
| Alcon Research LLC | $62,031.65 | 2019-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| New World Medical,INC. | $61,057.72 | 2019-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Ivantis, INC | $44,019.59 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36,185.37 | 2019-2021 | |
| Oyster Point Pharma, INC. | $33,858.46 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Eyepoint US, INC. | $20,133.45 | 2019-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18,727.30 | 2019-2022 | |
| Iridex Corporation | $17,229.89 | 2019-2024 | |
| Lumenis Ltd. | $15,000.00 | 2019-2021 | |
| Dompe US, INC. | $12,317.43 | 2022-2023 | Oxervate |
| Kala Pharmaceuticals, INC. | $12,122.63 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $8,986.59 | 2023-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Carl Zeiss Meditec, INC. | $7,257.71 | 2019-2025 | Visumax, Cirrus Hd-Oct, Veracity Surgical |
| Alimera Sciences, INC. | $5,738.94 | 2020-2024 | Iluvien, Yutiq |
| Lumenis Be INC | $3,000.00 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $2,664.00 | 2022 | |
| Thea Pharma INC. | $2,574.27 | 2022-2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $2,294.45 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $1,566.11 | 2019-2024 | Tecnis Iol |
| Lumenis, INC | $1,000.00 | 2021 | |
| Lensar, INC. | $700.00 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $544.25 | 2021-2024 | Iolmaster 700, Quatera 700, Humphrey Hfa |
| Sun Pharmaceutical Industries INC. | $375.85 | 2019-2023 | Cequa, Bromsite, Xelpros |
| Harrow Eye, LLC | $293.56 | 2024-2025 | Vevye, Triesence |
| Biotissue Holdings INC. | $255.86 | 2021-2022 | |
| Rxsight INC | $234.37 | 2021-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Eyevance Pharmaceuticals LLC | $207.67 | 2019-2022 | |
| Shire North American Group INC | $185.15 | 2019 | |
| Ocular Therapeutix, INC. | $159.56 | 2019-2023 | Dextenza |
| Carl Zeiss Meditec Cataract Technology INC. | $108.47 | 2023 | |
| Quidel Corporation | $96.58 | 2019 | |
| Staar Surgical Company | $52.71 | 2019 | |
| Genentech USA, INC. | $46.80 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $28.58 | 2020 | |
| Horizon Therapeutics Plc | $22.43 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$55,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Radcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.